智通财经APP获悉，药捷安康-B(02617)尾盘跌近18%，低见150.2港元，较周二盘中高点679.5港元已跌超77%。截至发稿，跌17.9%，报150.4港元，成交额6.02亿港元，总市值596.93亿港元。
公开资料显示，药捷安康今年6月23日在港交所上市，发行价为13.15港元，总股本约3.97亿股，上市时总市值约52亿港元。其IPO公开发行1528.1万股，其中基石投资者认购约979万股，实际流通股仅约549万股。市场流通盘小意味着药捷安康在二级市场上的可交易筹码极为有限。
值得注意的是，9月8日，药捷安康同时被纳入恒生创新药指数、恒生港股通创新药指数及恒生港股通创新药精选指数。9月15日，药捷安康被纳入“国证港股通创新药指数”。市场人士指出，药捷安康在指数中的初始权重约为2.63%，据推算相关指数基金需被动配置至少超过6亿港元的该股票，由此触发股价剧烈波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.